


## PHARMACEUTICAL 2017



## Statera Biopharma Inc. Rank 60 of 313







## PHARMACEUTICAL 2017



## Statera Biopharma Inc. Rank 60 of 313



The relative strengths and weaknesses of Statera Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Statera Biopharma Inc. compared to the market average is the variable Other Net Income, increasing the Economic Capital Ratio by 318% points. The greatest weakness of Statera Biopharma Inc. is the variable Revenues, reducing the Economic Capital Ratio by 114% points.

The company's Economic Capital Ratio, given in the ranking table, is 33%, being 450% points above the market average of -417%.

Input Variable	Value in 1000 USD
Assets, Current	15,888
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	3,109
Liabilities, Non-Current	0
Other Assets	31
Other Compr. Net Income	-218
Other Expenses	0
Other Liabilities	0
Other Net Income	7,284
Property and Equipment	37
Research and Development	6,496
Revenues	0
Selling, General and Administrative Expense	3,378

Output Variable	Value in 1000 USD
Assets	15,956
Liabilities	3,109
Expenses	9,874
Stockholders Equity	12,847
Net Income	-2,590
Comprehensive Net Income	-2,699
Economic Capital Ratio	33%